22972-63-0

Usage

Uses

Used in Pharmaceutical Synthesis:
2-(3,5-DIMETHOXY-PHENYL)-2-METHYL-PROPIONITRILE is used as an intermediate in the pharmaceutical industry for the synthesis of various pharmaceutical compounds. Its role in the production process is crucial for creating a range of medications that can address different health conditions.
Used in Agrochemical Production:
In the agrochemical sector, 2-(3,5-DIMETHOXY-PHENYL)-2-METHYL-PROPIONITRILE is utilized as a key component in the formulation of various agrochemicals. Its application aids in the development of products designed to protect crops and enhance agricultural productivity.
Used as a Building Block in Organic Synthesis:
2-(3,5-DIMETHOXY-PHENYL)-2-METHYL-PROPIONITRILE is used as a building block in the synthesis of other organic compounds. Its structural properties make it a valuable component in the creation of a diverse array of chemical products.
Used in Antifungal and Antimicrobial Applications:
DMPN has been studied for its potential pharmacological activities, including its use as an antifungal and antimicrobial agent. It is employed in applications where control of fungal and microbial growth is necessary, such as in medical and environmental settings.

InChI:InChI=1/C12H15NO2/c1-12(2,8-13)9-5-10(14-3)7-11(6-9)15-4/h5-7H,1-4H3

Upstream product

• 13388-75-5 3,5-dimethoxyphenylacetonitrile 
• 74-88-4 methyl iodide 
• 78-82-0 Isobutyronitrile 
• 52189-63-6 3,5-dimethoxyfluorobenzene 
• 7311-34-4 3,5-dimethoxybenzaldehdye 
• 6652-32-0 3,5-dimethoxybenzylchloride 
• 705-76-0 3,5-dimethoxybenzyl alcohol 

Downstream Products

• 65511-87-7 2-methyl-2-(3,5-dimethoxyphenyl)-5-phenyl-3-pentanone 
• 1515519-30-8 2-(3,5-dimethoxyphenyl)-2-methylpropan-1-ol 
• 197587-20-5 3,5-dimethoxy-1-(2-methyl-8-phenoxyoctan-2-yl)benzene 
• 1309372-84-6 HU 910 
• 60526-81-0 1-(1',1'-dimethylheptyl)-3,5-dimethoxybenzene 
• 1309372-78-8 HU 912 
• 1309372-88-0 HU 914 
• 1605280-98-5 (Z)-3,5-dimethoxy-1-(2-methyl-8-phenoxyoct-3-en-2-yl)benzene 
• 105823-04-9 JWH 057 
• 22663-41-8 (6aR,10aR)-6,6,9-trimethyl-3-(2-methylhexan-2-yl)-6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-1-ol 
• 120078-30-0 2-(3,5-dimethoxyphenyl)-2-methylpropanal 

Relevant academic research and scientific papers

Novel Functionalized Cannabinoid Receptor Probes: Development of Exceptionally Potent Agonists

We report the development of novel cannabinergic probes that can stabilize the cannabinoid receptors (CBRs) through tight binding interactions. Ligand design involves the introduction of select groups at a judiciously chosen position within the classical

Novel Labelled Cannabinergic Ligands and Related Analogs

Novel cannabinoid ligands represented by the general formulas I, II, and III and methods for preparation and use within which one or more of a fluorescent ligand, nitroxide spin label, metal chelate, biotin moiety, or group with enhanced polarity may be incorporated. The compounds can bind to and modulate the cannabinoid CB1 and CB2 receptors and thereby considered specific ligands for these receptors. Some of the disclosed compounds that bind to cannabinoid CB1 and CB2 receptors can exhibit tight or irreversible binding characteristics for these receptors. Due to the presence of the imaging/diagnostic and/or therapeutic functional groups including fluorescent groups, nitroxide spin labels, metal chelates, biotin moieties, and groups with enhanced polarity, the disclosed compounds may be useful as imaging/diagnostic tools and/or therapeutic agents.

CANNABINOIDS AND USES THEREOF

The invention relates to cannabinoid compounds, pharmaceutical compositions including one or more cannabinoid compounds, and the use of pharmaceutical compositions including one or more cannabinoid compounds for the treatment of a disease or condition (e.

PROCESS FOR THE PREPARATION OF HU-910 AND CRYSTALLINE STRUCTURE THEREOF

The invention provides processes for the preparation of HU-910, which are scalable to industrial purposes, using safer reagents and having high yield and pure product and a crystalline structure of HU-910, which is a unique product thereof.

Synthesis, radio-synthesis and in vitro evaluation of terminally fluorinated derivatives of HU-210 and HU-211 as novel candidate PET tracers

We report the synthesis of terminally fluorinated HU-210 and HU-211 analogues (HU-210F and HU-211F, respectively) and their biological evaluation as ligands of cannabinoid receptors (CB1 and CB2) and N-methyl d-aspartate receptor (NMDAR). [18F]-labelled HU-210F was radiosynthesised from the bromo-substituted precursor. In vitro assays showed that both HU-210F and HU-211F retain the potent pharmacological profile of HU-210 and HU-211, suggesting that [18F]-radiolabelled HU-210F and HU-211F could have potential as PET tracers for in vivo imaging.

Crystal structures of agonist-bound human cannabinoid receptor CB 1

The cannabinoid receptor 1 (CB 1) is the principal target of the psychoactive constituent of marijuana, the partial agonist " 9 -tetrahydrocannabinol (Δ9 -THC). Here we report two agonist-bound crystal structures of human CB 1 in complex with a tetrahydro

2-CYCLOALKYL RESORCINOL CANNABINERGIC LIGANDS

The present invention relates to novel 2-cycloalkyl resorcinol compounds; to pharmaceutical compositions comprising the compounds; and to methods of preparing the compounds and uses thereof. The disclosed compounds can bind to and modulate the cannabinoid

Controlled-deactivation cannabinergic ligands

We report an approach for obtaining novel cannabinoid analogues with controllable deactivation and improved druggability. Our design involves the incorporation of a metabolically labile ester group at the 2′-position on a series of (-)-Δ8-THC a

PPAR active compounds

Compounds are described that are active on at least one of PPARα, PPARδ, and PPARγ, which are useful for therapeutic and/or prophylactic methods involving modulation of at least one of PPARα, PPARδ, and PPARγ.

Process for preparing benzylnitriles

A process is described for preparing an aromatic compound substituted by a tertiary nitrile of Formula (1.0.0): comprising treating a substituted aromatic compound of Formula (2.0.0): with a secondary nitrile of Formula (3.0.0): in the presence of a base having a pKanumerical value in the range of from about 17 to about 30, provided that the difference in pKanumerical values between said base and the corresponding tertiary nitrile of Formula (3.0.0) is no more than about 6; in an aprotic solvent having a dielectric constant (∈) of less than about 20; and at a reaction temperature in the range of from about 0° C. to about 120° C.; whereby there is formed said tertiary-nitrile-substituted aromatic compound final product of Formula (1.0.0); wherein the constituent parts W1, W2, W3, W4, and W5; and the substituent moieties R1, R2, R3, R4, R5, R6, and R7in the compounds of Formulas (1.0.0), (2.0.0) and (3.0.0) are selected from known organic groups and radicals as further detailed in the instant specification.